Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 17 peer-reviewed journal articles Updated
Nephrology

Treatment Strategy: C5 Inhibitors and Standard of Care

At a Glance

The standard treatment for atypical hemolytic uremic syndrome (aHUS) is C5 inhibitors, such as eculizumab and ravulizumab. These medications block the immune system from damaging blood vessels. Because they suppress the immune system, patients must be vaccinated against meningitis.

The treatment of atypical Hemolytic Uremic Syndrome (aHUS) has been transformed by a class of medications called C5 inhibitors [1]. These drugs are monoclonal antibodies—man-made proteins that act like targeted “shields” to block a specific part of your immune system (the terminal complement system) from attacking your blood vessels [2][3].

The Standard of Care: C5 Inhibitors

For most patients, C5 inhibitors are the first-line treatment for aHUS [1][4]. They work by stopping the complement system at the “C5” step, which prevents the formation of the “Membrane Attack Complex” that shreds blood cells and damages organs [2][5].

There are currently two primary C5 inhibitors used:

  • Eculizumab (Soliris): The first approved treatment for aHUS. It is typically given as an intravenous (IV) infusion once a week for the first few weeks (the “loading phase”) and then every two weeks (the “maintenance phase”) [1][6].
  • Ravulizumab (Ultomiris): A next-generation version of eculizumab. It was engineered to last longer in the body, allowing for a much less frequent schedule. After the initial loading doses, it is typically given every eight weeks [2][7].

Many patients and caregivers prefer ravulizumab because the eight-week schedule significantly reduces the “healthcare burden,” meaning fewer hospital visits and less time away from school or work [8][9].

The Importance of “Ultra-Early” Treatment

When it comes to aHUS, time is tissue—specifically kidney tissue. Clinical guidelines emphasize that C5 inhibitors should be started as early as possible, ideally within 48 hours of the disease being suspected [4][10].

  • Reversing Damage: Early treatment can stop the tiny clots from forming and allow the kidneys to begin healing. In many cases, patients who required dialysis at the start of their flare were able to stop dialysis once the C5 inhibitor began working [6][11]. Note that this recovery can take weeks or months.
  • Long-Term Outlook: The sooner the complement system is “turned off,” the better the chances of preserving long-term kidney function and preventing permanent scarring [4][6].

The Role of Plasma Exchange (PEX)

Before C5 inhibitors existed, plasma exchange (filtering the liquid part of the blood and replacing it with donor plasma) was the only treatment available [12]. Today, its role has changed:

  • As a “Bridge”: Doctors may start PEX immediately if they aren’t sure yet if the patient has TTP or aHUS, as PEX is the primary treatment for TTP [12][13].
  • For Anti-CFH Antibodies: If a patient has the autoimmune form of aHUS (anti-CFH antibodies), PEX is often used alongside C5 inhibitors and immunosuppressant drugs to physically remove the harmful antibodies from the blood [14][15].
  • Limited Benefit: For the genetic form of aHUS, PEX is generally less effective than C5 inhibitors because it doesn’t stop the complement system from reactivating almost immediately [16][17].

Safety and Monitoring: The Meningococcal Warning

Because C5 inhibitors block a part of your immune system, they carry a black-box warning for increasing the risk of serious infections, specifically meningococcal disease [1]. To stay safe, you MUST:

  1. Get Fully Vaccinated: You must be vaccinated against both MenACWY and MenB [1]. This is a critical safety point; ask your doctor explicitly to verify you received both types of meningitis vaccines.
  2. Prophylactic Antibiotics: Take daily preventive antibiotics if your doctor prescribes them [4].
  3. Carry a Safety Card: Carry a patient safety card at all times to alert emergency doctors to your condition and medication [1].

Common questions in this guide

What is the standard treatment for aHUS?
The first-line treatment for atypical hemolytic uremic syndrome is a class of medications called C5 inhibitors. These include eculizumab (Soliris) and ravulizumab (Ultomiris), which block the immune system from damaging blood vessels.
What is the difference between eculizumab and ravulizumab?
Both are C5 inhibitors used to treat aHUS, but they have different dosing schedules. Eculizumab is typically given as an intravenous infusion every two weeks, while ravulizumab is a longer-lasting version given every eight weeks.
How quickly should aHUS treatment begin?
Treatment with C5 inhibitors should ideally begin within 48 hours of suspecting aHUS. Early treatment is crucial to stop blood clots from forming and to prevent permanent kidney damage.
When is plasma exchange used for aHUS?
Plasma exchange is often used as an initial bridge treatment before a definitive diagnosis is made or if another condition like TTP is suspected. It is also used in cases of autoimmune aHUS to remove harmful anti-CFH antibodies from the blood.
Why is the meningitis vaccine required before starting C5 inhibitors?
C5 inhibitors block a specific part of the immune system, which significantly increases the risk of serious infections like meningococcal disease. Patients must receive both MenACWY and MenB vaccines to protect themselves safely.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.How soon after the onset of my (or my child's) symptoms was the first dose of a C5 inhibitor administered?
  2. 2.Are we planning to use eculizumab (every 2 weeks) or ravulizumab (every 8 weeks), and what factor determines that choice?
  3. 3.If we are starting with plasma exchange, is it because we are waiting for a definitive diagnosis or because of suspected anti-CFH antibodies?
  4. 4.Can you confirm that I have received both the MenACWY and MenB vaccinations, and what is our plan for prophylactic antibiotics?
  5. 5.What signs of kidney recovery are we looking for in the first few weeks of treatment?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (17)
  1. 1

    Safety Profile of Monoclonal Antibodies and Subsequent Drug Developments in the Treatment of Paroxysmal Nocturnal Hemoglobinuria.

    Mallenahalli Neeekantappa V, Kamath A, Bharathi Rajaduraivelpandian P

    Medicina (Kaunas, Lithuania) 2024; (60(3)) doi:10.3390/medicina60030379.

    PMID: 38541105
  2. 2

    Ravulizumab facilitates reduced burden of vascular access, a major benefit in paediatric atypical haemolytic uraemic syndrome.

    Bleathman F, Kausman JY, Hosking LM, Forbes TA

    Journal of paediatrics and child health 2024; (60(6)):183-187 doi:10.1111/jpc.16552.

    PMID: 38661088
  3. 3

    Ravulizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder.

    Pittock SJ, Barnett M, Bennett JL, et al.

    Annals of neurology 2023; (93(6)):1053-1068 doi:10.1002/ana.26626.

    PMID: 36866852
  4. 4

    [Ultra-early administration of eculizumab in a child with atypical hemolytic uremic syndrome: a case report].

    Guo DD, Xiao YX, Wang WR, et al.

    Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics 2025; (27(11)):1408-1413 doi:10.7499/j.issn.1008-8830.2503084.

    PMID: 41250542
  5. 5

    Atypical Hemolytic Uremic Syndrome.

    Dixon BP, Gruppo RA

    Pediatric clinics of North America 2018; (65(3)):509-525 doi:10.1016/j.pcl.2018.02.003.

    PMID: 29803280
  6. 6

    Pharmacological Management of Atypical Hemolytic Uremic Syndrome in Pediatric Patients: Current and Future.

    Gurevich E, Landau D

    Paediatric drugs 2023; (25(2)):193-202 doi:10.1007/s40272-022-00555-6.

    PMID: 36637720
  7. 7

    Ravulizumab 100 mg/mL formulation reduces infusion time and frequency, improving the patient and caregiver experience in the treatment of atypical haemolytic uraemic syndrome.

    Dixon BP, Sabus A

    Journal of clinical pharmacy and therapeutics 2022; (47(7)):1081-1087 doi:10.1111/jcpt.13642.

    PMID: 35304755
  8. 8

    Treatment preference and quality of life impact: ravulizumab vs eculizumab for atypical hemolytic uremic syndrome.

    Mauch TJ, Chladek MR, Cataland S, et al.

    Journal of comparative effectiveness research 2023; (12(9)):e230036 doi:10.57264/cer-2023-0036.

    PMID: 37515502
  9. 9

    An evaluation of ravulizumab for the treatment of neuromyelitis optica spectrum disorder.

    Balaban DT, Levy M, Borrow R, Anderson MR

    Expert opinion on biological therapy 2024; (24(11)):1193-1198 doi:10.1080/14712598.2024.2423002.

    PMID: 39460545
  10. 10

    The Importance of Eculizumab in the Treatment of Atypical Hemolytic Uremic Syndrome.

    Santos MS, Ventura S, Alves A, et al.

    Cureus 2022; (14(6)):e25743 doi:10.7759/cureus.25743.

    PMID: 35812637
  11. 11

    Is eculizumab indicated in patients with atypical hemolytic uremic syndrome already on prolonged dialysis? A case report and review of the literature.

    Haskin O, Falush Y, Davidovits M

    Pediatric nephrology (Berlin, Germany) 2019; (34(12)):2601-2604 doi:10.1007/s00467-019-04341-4.

    PMID: 31520126
  12. 12

    POSTPARTUM RENAL THROMBOTIC MICROANGIOPATHY: A TURN-BASED DIFFERENTIAL DIAGNOSIS.

    Markin L, Shatylovych K

    Wiadomosci lekarskie (Warsaw, Poland : 1960) 2022; (75(1)):128-131.

    PMID: 35092261
  13. 13

    Coronavirus disease 2019-associated thrombotic microangiopathy treated with plasma exchange and antihypertensive therapy in a patient with HIV: A case report with literature review.

    Masuda E, Fukushima K, Hebisawa Y, et al.

    Medicine 2023; (102(41)):e35469 doi:10.1097/MD.0000000000035469.

    PMID: 37832064
  14. 14

    Long-Term Outcomes of Anticomplement Factor H Antibody Positive Versus Negative Atypical Hemolytic Uremic Syndrome.

    Veeranki V, Meyyappan J, Srivastava A, et al.

    Indian journal of nephrology 2025; (35(3)):402-409 doi:10.25259/IJN_106_2024.

    PMID: 40352901
  15. 15

    Efficacy of cascade plasmapheresis in comparison with conventional therapeutic plasma exchange for relapsed atypical hemolytic uremic syndrome: A case report.

    Vaidya A, Polavarapu I, Prabhu RA, et al.

    Asian journal of transfusion science 2022; (16(2)):283-286 doi:10.4103/ajts.ajts_121_21.

    PMID: 36687548
  16. 16

    Atypical hemolytic-uremic syndrome: recurrent phenotypic expression of a patient with MCP gene mutation combined with risk haplotypes.

    Marini SC, Gomes M, Guilherme R, et al.

    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 2019; (30(2)):68-70 doi:10.1097/MBC.0000000000000793.

    PMID: 30676336
  17. 17

    The Differential Diagnosis and Treatment of Thrombotic Microangiopathies.

    Bommer M, Wölfle-Guter M, Bohl S, Kuchenbauer F

    Deutsches Arzteblatt international 2018; (115(19)):327-334.

    PMID: 29875054

This page explains aHUS treatment options for educational purposes. Your nephrologist or hematologist is the best source for choosing the right therapy and managing your specific care plan.

Get notified when new evidence is published on Atypical hemolytic uremic syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.